Sign up to save your podcasts
Or
Share ACC CardiaCast: Emerging Data in SGLT2 Inhibitors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACC CardiaCast: Emerging Data in SGLT2 Inhibitors
This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.
View all episodes
By American College of Cardiology
4.4
3737 ratings
This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.
More shows like ACC CardiaCast
View all
NEJM This Week
321 Listeners
JAMA Clinical Reviews
504 Listeners
JACC This Week
167 Listeners
Heart Podcast
41 Listeners
This Week in Cardiology
906 Listeners
JACC Specialty Journals
21 Listeners
Talking Points
3 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
138 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
65 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
ESC Cardio Talk
19 Listeners
Cardionerds: A Cardiology Podcast
437 Listeners
Mayo Clinic Cardiovascular CME
32 Listeners